Company Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-22 pm EDT			5-day change	1st Jan Change
1.27 ^USD	+8.55%		-13.61%	+86.76%

Apr. 18	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
Apr. 18	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Number of employees: 33

Managers	Title	Age	Since
Michael Tardugno CHM	Chairman	73	07-01-02
Jeffrey Church DFI	Director of Finance/CFO	67	10-07-05
Sebastien Hazard CTO	Chief Tech/Sci/R&D Officer	53	Dec. 10
Khursheed Anwer CTO	Chief Tech/Sci/R&D Officer	64	14-06-19
Kimberly Bragg AUD	Comptroller/Controller/Auditor	-	-

Members of the board	Title	Age	Since
Christine Pellizzari BRD	Director/Board Member	56	21-06-07
Frederick Fritz BRD	Director/Board Member	73	11-07-07
James Dentzer BRD	Director/Board Member	57	22-10-02
Michael Tardugno CHM	Chairman	73	07-01-02
Donald Braun BRD	Director/Board Member	74	15-12-14
Stacy Lindborg BRD	Director/Board Member	53	21-06-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,399,811	9,291,441 ( 98.85 %)	22 ( 0.000234 %)	98.85 %

Name	Equities	%	Valuation
Renaissance Technologies LLC 0.9800 %	92,111	0.9800 %	151 062 $
Geode Capital Management LLC 0.7085 %	66,595	0.7085 %	109 216 $
BlackRock Institutional Trust Co. NA 0.6233 %	58,584	0.6233 %	96 078 $
Vanguard Global Advisers LLC 0.5428 %	51,019	0.5428 %	83 671 $
Citadel Securities GP LLC 0.3152 %	29,628	0.3152 %	48 590 $
HRT Financial LLC 0.3039 %	28,569	0.3039 %	46 853 $
Virtu Financial LLC 0.2751 %	25,860	0.2751 %	42 410 $
G1 Execution Services LLC 0.2433 %	22,864	0.2433 %	37 497 $
Sebastien Hazard 0.2128 %	20,000	0.2128 %	32 800 $
Michael Tardugno 0.1757 %	16,513	0.1757 %	27 081 $

Imunon, Inc.

997 Lenox Drive Suite 100

08648, Lawrenceville

+609 896 9100

http://imunon.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.27 USD

Average target price

12 USD

Spread / Average Target

+844.88%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
IMUNON, INC.	+86.76%	11.94M
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	+0.35%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.34%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B

Bio Therapeutic Drugs